Download PDF
Pharmacopsychiatry 2004; 37: 126-135
DOI: 10.1055/s-2004-832666
Schizophrenia
© Georg Thieme Verlag KG Stuttgart · New York

Course and Long-Term Treatment of Schizophrenic Psychoses

H.-J. Möller1
  • 1Psychiatrische Klinik der Ludwig-Maximilians-Universität, München, Germany
Further Information

Publication History

Publication Date:
16 November 2004 (online)

Also available at
    Permissions and Reprints

As there is a lack of clear biological correlates for most psychiatric disorders, follow-up studies regarding course, outcome and prognosis of psychiatric disorders play an important role in psychiatric research, especially in terms of validation of psychiatric diagnoses and other psychiatric concepts, such as the concept of negative symptoms. Long-term studies also have their place in the description and evaluation of first treatment procedures. The first part of this paper will describe some general aspects of the long-term course and outcome of schizophrenic psychoses. The problem of relapses and relapse prevention will then be discussed. Especially data from recent studies will be considered in this overview.

References

  • 1 Arato M, O’Connor R, Meltzer H. Zeus study group. Ziprasidone in the long-term treatment of negative symptoms and the prevention of exacerbation of schizophrenia.  Int Clin Psychopharmacol. 2002;  17 207-215
    Google Scholar
  • 2 Bäuml J, Kissling W, Meurer C, Wais A, Lauter H. Informationszentrierte Angehörigengruppe zur Complianceverbesserung bei schizophrenen Patienten.  Psychiatr Prax. 1991;  18 48-54
    PubMedGoogle Scholar
  • 3 Beasley C, Hamilton S, Dossenbach M. Relapse prevention with olanzapine.  Eur Neuropsychopharmacol. 2000;  10 S304
    PubMedGoogle Scholar
  • 4 Bleuler M. Dementia Praecox or the group of schizophrenias. New York; International University Press 1950
    Google Scholar
  • 5 Bottlender R, Jager M, Groll C, Strauss A, Moller H J. Deficit states in schizophrenia and their association with the length of illness and gender.  Eur Arch Psychiatry Clin Neurosci. 2001;  251 272-278
    PubMedGoogle Scholar
  • 6 Bottlender R, Sato T, Jager M, Wegener U, Wittmann J, Strauss A. et al . The impact of the duration of untreated psychosis prior to first psychiatric admission on the 15-year outcome in schizophrenia.  Schizophr Res. 2003;  62 37-44
    CrossrefPubMedGoogle Scholar
  • 7 Bottlender R, Strauß A, Möller H J. Impact of duration of symptoms prior to first hospitalization on acute outcome in 998 schizophrenic patients.  Schizophrenia Research. 2000;  44 145-150
    CrossrefPubMedGoogle Scholar
  • 8 Buchkremer G, Schulze-Mönking H, Holle R, Hornung W P. The impact of therapeutic relatives’ groups on the course of illness of schizophrenic patients.  Eur Psychiatry. 1995;  10 17-27
    CrossrefPubMedGoogle Scholar
  • 9 Carpenter Jr W T, Heinrichs D W, Wagman A M. Deficit and nondeficit forms of schizophrenia: the concept.  Am J Psychiatry. 1988;  145 578-583
    PubMedGoogle Scholar
  • 10 Cheung H K. Schizophrenics fully remitted on neuroleptics for 3-5 years - to stop or continue drugs.  Br J Psychiat. 1981;  138 490-494
    CrossrefPubMedGoogle Scholar
  • 11 Cooper S J, Butler A, Tweed J, Welch C, Raniwalla J. Zotepine in the prevention of recurrence: a randomised, double-blind, placebo-controlled study for chronic schizophrenia.  Psychopharmacology (Berl). 2000;  150 237-243
    CrossrefPubMedGoogle Scholar
  • 12 Cramer J A, Rosenheck R. Compliance with medication regimens for mental and physical disorders.  Psychiatr Serv. 1998;  49 196-201
    PubMedGoogle Scholar
  • 13 Csernansky J G, Mahmoud R, Brenner R. A comparison of risperidone and haloperidol for the prevention of relapse in patients with schizophrenia.  N Engl J Med. 2002;  346 16-22
    CrossrefPubMedGoogle Scholar
  • 14 Daniel D G, Wozniak P, Mack R J, McCarthy B G. Long-term efficacy and safety comparison of sertindole and haloperidol in the treatment of schizophrenia. The Sertindole Study Group.  Psychopharmacol Bull. 1998;  34 61-69
    PubMedGoogle Scholar
  • 15 Davis J M, Matalon L, Watanabe M D, Blake L, Matalon L. Depot antipsychotic drugs. Place in therapy.  Drugs. 1994;  47 741-773
    CrossrefPubMedGoogle Scholar
  • 16 Dellva M A, Tran P, Tollefson G D, Wentley A L, Beasley C -MJ. Standard olanzapine versus placebo and ineffective-dose olanzapine in the maintenance treatment of schizophrenia.  Psychiatr Serv. 1997;  48 1571-1577
    PubMedGoogle Scholar
  • 17 Essock S M, Hargreaves W A, Covell N H, Goethe J. Clozapine’s effectiveness for patients in state hospitals: results from a randomized trial.  Psychopharmacol Bull. 1996;  32 683-697
    PubMedGoogle Scholar
  • 18 Fenton W S. Course and outcome in schizophrenia.  Curr Opin Psychiatry. 1997;  10 40-44
    CrossrefPubMedGoogle Scholar
  • 19 Gaebel W. Is intermittent, early intervention medication an alternative for neuroleptic maintenance treatment?.  Int Clin Psychopharmacol. 1995;  9 (Supl 5) 11-16
    PubMedGoogle Scholar
  • 20 Goldberg J F, Harrow M, Grossman L S. Course and outcome in bipolar affective disorder: a longitudinal follow-up study.  Am J Psychiatry. 1995;  152 379-384
    PubMedGoogle Scholar
  • 21 Goldberg S C, Schooler N R, Hogarty G E, Roper M. Prediction of relapse in schizophrenic outpatients treated by drug and sociotherapy.  Arch Gen Psychiatry. 1977;  34 171-184
    PubMedGoogle Scholar
  • 22 Grossman L S, Harrow M, Goldberg J F, Fichtner C G. Outcome of schizoaffective disorder at two long-term follow-ups: comparisons with outcome of schizophrenia and affective disorders.  Am J Psychiatry. 1991;  148 1359-1365
    PubMedGoogle Scholar
  • 23 Hirsch S R, Gaind R, Rohde P D, Stevens B C, Wing J K. Outpatient maintenance of chronic schizophrenic patients with long-acting fluphenazine: double-blind placebo trial. Report to the Medical Research Council Committee on Clinical Trials in Psychiatry.  Br Med J. 1973;  1 633-637
    PubMedGoogle Scholar
  • 24 Hogarty G E, Goldberg S, Schooler N, Ulrich R. Drug and sociotherapy in the aftercare of schizophrenic patients. II. Two-years relapse rates.  Arch Gen Psychiatry. 1974;  31 603-608
    PubMedGoogle Scholar
  • 25 Hogarty G E, Goldberg S C. Drug and sociotherapy in the aftercare of schizophrenic patients. One-year relapse rates.  Arch Gen Psychiatry. 1973;  28 54-64
    PubMedGoogle Scholar
  • 26 Jäger M, Bottlender R, Wegner U, Wittmann J, Strauss A, Möller H J. 15-Jahres-Katamnese schizophrener Psychosen im Vergleich zu affektiven und schizoaffektiven Psychosen. In: Möller HJ, Müller N, (eds) Schizophrenie: Langzeitverlauf und Langzeittherapie. Wien; Springer 2004: 23-30
    Google Scholar
  • 27 Jolley A G, Hirsch S R, Morrison E, McRink A, Wilson L. Trial of brief intermittent neuroleptic prophylaxis for selected schizophrenic outpatients: clinical and social outcome at two years.  BMJ. 1990;  301 837-842
    PubMedGoogle Scholar
  • 28 Kane J M, Aguglia E, Altamura A C, Ayuso-Gutierrez J L, Brunello N, Fleischhacker W W. et al . Guidelines for depot antipsychotic treatment in schizophrenia. European Neuropsychopharmacology Consensus Conference in Siena, Italy.  Eur Neuropsychopharmacol. 1998;  8 55-66
    CrossrefPubMedGoogle Scholar
  • 29 Kraepelin E. Dementia Praecox. Edinburgh; E.S. Liningstone 1919
    Google Scholar
  • 30 Leff J P, Wing J K. Trial of maintenance therapy in schizophrenia.  Br Med J. 1971;  3 599-604
    PubMedGoogle Scholar
  • 31 Leucht S, Barnes T, Kissling W, Engel R, Kane J M. Relapse prevention in schizophrenia with new antipsychotics: a meta-analysis of randomized controlled trials.  Am J Psychiatry. 2003;  160 1209-1222
    Google Scholar
  • 32 Lieberman J A, Koreen A R, Chakos M, Sheitman B, Woerner M, Alvir J M. et al . Factors influencing treatment response and outcome of first-episode schizophrenia: implications for understanding the pathophysiology of schizophrenia.  J Clin Psychiatry. 1996;  57 Suppl 9 5-9
    PubMedGoogle Scholar
  • 33 Loo H, Poirier-Littre M F, Theron M, Rein W, Fleurot O. Amisulpride versus placebo in the medium-term treatment of the negative symptoms of schizophrenia.  Br J Psychiat. 1997;  170 18-22
    PubMedGoogle Scholar
  • 34 Marder S R, Glynn S M, Wirshing W C, Wirshing D A, Ross D, Widmark C. et al . Maintenance treatment of schizophrenia with risperidone or haloperidol: two years outcomes.  Am J Psychiatry. 2003;  160 1405-1412
    CrossrefPubMedGoogle Scholar
  • 35 Marder S R, Van Putten T, Mintz J, Lebell M, McKenzie J, May P R. Low- and conventional-dose maintenance therapy with fluphenazine decanoate. Two-year outcome.  Arch Gen Psychiatry. 1987;  44 518-521
    PubMedGoogle Scholar
  • 36 Marneros A, Deister A, Rohde A. Affektive, schizoaffektive und schizophrene Psychosen. Eine vergleichende Langzeitstudie. [Affective, schizoaffective and schizophrenic psychoses. A comparative long-term study].  Monogr Gesamtgeb Psychiatr Psychiatry Ser. 1991;  65 1-454
    PubMedGoogle Scholar
  • 37 McGlashan T H. A selective review of recent North American long-term followup studies of schizophrenia.  Schizophr Bull. 1988;  14 515-542
    PubMedGoogle Scholar
  • 38 Meltzer H Y, Alphs L, Green A, Altamura A C, Anand R, Bertoli A. et al . Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT).  Arch Gen Psychiatry. 2003;  60 82-91
    Google Scholar
  • 39 Möller H J. Neuroleptische Langzeittherapie schizophrener Erkrankungen. In: Heinrich K, (ed) Leitlinien neuroleptischer Therapie. Berlin Heidelberg New York; Springer 1990: 97-115
    Google Scholar
  • 40 Möller H J. Zur Vorhersage des mittelfristigen Verlaufs schizophrener Psychosen. In: Heinrich K, Klieser E, Lehmann E, (eds) Prädiktoren des Therapieverlaufs endogener Psychosen. Stuttgart New York; Schattauer 1993: 85-105
    Google Scholar
  • 41 Möller H J. Definition, psychopharmacological basis and clinical evaluation of novel/atypical neuroleptics: methodological issues and clinical consequences.  World J Biol Psychiatry. 2000;  1 75-91
    PubMedGoogle Scholar
  • 42 Möller H J. State of the art of drug treatment of schizophrenia and the future position of the novel/atypical antipsychotics.  World J Biol Psychiatry. 2000;  1 204-214
    PubMedGoogle Scholar
  • 43 Möller H J. Antipsychotic agents - gradually improving treatment. Br J Psychiat 2003: In Press
    Google Scholar
  • 44 Möller H J. Depressive Comorbidität/Co-syndromibidität im Rahmen schizophrener Psychosen und ihre Therapie. In: Fleischhacker WW, Hummer N (eds) Schizophrene Störungen. State of the Art 3. Innsbruck; VIP Verlag, 2004: 175-202
    Google Scholar
  • 45 Möller H J. Der Einsatz neuer Antipsychotika in der Langzeittherapie der Schizophrenie. In: Möller HJ, Müller N, (eds) Schizophrenie. Langzeitverlauf und Langzeittherapie. Vienna New York; Springer 2004: 247-266
    Google Scholar
  • 46 Möller H J, Bottlender R, Groß A, Hoff P, Wittmann J, Wegner U. et al . The Kraepelinian dichotomy: preliminary results of a 15-year follow-up study on functional psychoses: focus on negative symptoms.  Schizophr Res. 2002;  56 87-94
    CrossrefPubMedGoogle Scholar
  • 47 Möller H J, Bottlender R, Wegner U, Wittmann J, Strauß A. Long-term course of schizophrenic, affective and schizoaffective psychosis: focus on negative symptoms and their impact on global indicators of outcome.  Acta Psychiatr Scand. 2000;  102 (Suppl 407) 54-57
    CrossrefPubMedGoogle Scholar
  • 48 Möller H J, Deister A. Schizophrenie. In: Möller HJ, Laux G, Kapfhammer H-P, (eds) Psychiatrie und Psychotherapie. Berlin Heidelberg New York; Springer 2000: 997-1068
    Google Scholar
  • 49 Möller H J, Gagiano C A, Addington D E, Von Knorring L, Torres-Plank J -F, Gaussares C. Long-term treatment of chronic schizophrenia with risperidone: an open-label, multicenter study of 386 patients.  Int Clin Psychopharmacol. 1998;  13 99-106
    PubMedGoogle Scholar
  • 50 Möller H J, Hohe-Schramm M, Cording-Tömmel C, Schmid Bode W, Wittchen H U, Zaudig M. et al . The classification of functional psychoses and its implications for prognosis.  Br J Psychiatry. 1989;  154 467-472
    CrossrefPubMedGoogle Scholar
  • 51 Möller H J, Kissling W, Stoll K D, Wendt G. Psychopharmakotherapie. Ein Leitfaden für Klinik und Praxis. Stuttgart; Kohlhammer 1989
    Google Scholar
  • 52 Möller H J, Schmid Bode W, Cording-Tömmel C, Wittchen H U, Zaudig M, von Zerssen D. Psychopathological and social outcome in schizophrenia versus affective/schizoaffective psychoses and prediction of poor outcome in schizophrenia. Results from a 5 - 8 year follow-up.  Acta Psychiatr Scand. 1988;  77 379-389
    PubMedGoogle Scholar
  • 53 Möller H J, von Zerssen D. Der Verlauf schizophrener Psychosen unter den gegenwärtigen Behandlungsbedingungen. Berlin Heidelberg New York; Springer 1986
    Google Scholar
  • 54 Müller P. Die Patienten und das Ergebnis der Rezidivprophylaxe. In: Müller P, (ed) Zur Rezidivprophylaxe schizophrener Psychosen. Stuttgart; Enke 1982: 15-23
    Google Scholar
  • 55 Oehl M, Hummer M, Fleischhacker W W. Compliance with antipsychotic treatment.  Acta Psychiatr Scand Suppl. 2000;  102 83-86
    PubMedGoogle Scholar
  • 56 Rabinowitz J, Lichtenberg P, Kaplan Z, Mark M, Nahon D, Davidson M. Rehospitalization rates of chronically ill schizophrenic patients discharged on a regimen of risperidone, olanzapine, or conventional antipsychotics.  Am J Psychiatry. 2001;  158 266-269
    CrossrefPubMedGoogle Scholar
  • 57 Riedel M, Strassnig M, Möller H J, Müller N. Die Stellung der Depot-Neuroleptika aus heutiger Sicht. In: Möller HJ, Müller N, (eds) Schizophrenia. Langzeitverlauf und Langzeittherapie. Vienna New York; Springer 2004: 215-231
    Google Scholar
  • 58 Rifkin A, Quitkin F, Rabiner C J, Klein D F. Fluphenazine decanoate, fluphenazine hydrochloride given orally, and placebo in remitted schizophrenics. I. Relapse rates after one year.  Arch Gen Psychiatry. 1977;  34 43-47
    PubMedGoogle Scholar
  • 59 Rosenheck R, Chang S, Choe Y, Cramer J, Xu W, Thomas J. et al . Medication continuation and compliance: a comparison of patients treated with clozapine and haloperidol.  J Clin Psychiatry. 2000;  61 382-386
    PubMedGoogle Scholar
  • 60 Rosenheck R, Evans D, Herz L, Cramer J, Xu W, Thomas J. et al . How long to wait for a response to clozapine: a comparison of time course of response to clozapine and conventional antipsychotic medication in refractory schizophrenia.  Schizophr Bull. 1999;  25 709-719
    PubMedGoogle Scholar
  • 61 Sheperd M. A Study of the Major Psychoses in an English Country. London; Chapman and Hall 1957
    Google Scholar
  • 62 Speller J C, Barnes T R, Curson D A, Pantelis C, Alberts J L. One-year, low-dose neuroleptic study of in-patients with chronic schizophrenia characterised by persistent negative symptoms. Amisulpride v. haloperidol.  Br J Psychiatry. 1997;  171 564-568
    PubMedGoogle Scholar
  • 63 Tamminga C A, Thaker G K, Moran M, Kakigi T, Gao X M. Clozapine in tardive dyskinesia: observations from human and animal model studies.  J Clin Psychiatry. 1994;  55 (Suppl B) 102-106
    PubMedGoogle Scholar
  • 64 Tran P V, Dellva M A, Tollefson G D, Wentley A L, Beasley C -M. Oral olanzapine versus oral haloperidol in the maintenance treatment of schizophrenia and related psychoses.  Br J Psychiatry. 1998;  172 499-505
    CrossrefPubMedGoogle Scholar
  • 65 Tsuang M T, Woolson R F, Fleming J A. Long-term outcome of major psychoses. I. Schizophrenia and affective disorders compared with psychiatrically symptom-free surgical conditions.  Arch Gen Psychiatry. 1979;  36 1295-1301
    PubMedGoogle Scholar
  • 66 Volz H P, Kasper S, Möller H J, Sachs G, Höse A. Die Rolle der Kognition in der Therapie schizophrener Störungen. Wiesbaden; Deutscher Universitäts-Verlag 2003
    Google Scholar
  • 67 Watt D C, Katz K, Shepherd M. The natural history of schizophrenia: a 5-year prospective follow-up of a representative sample of schizophrenics by means of a standardized clinical and social assessment.  Psychol Med. 1983;  13 663-670
    CrossrefPubMedGoogle Scholar

Prof. Dr. Hans-Jürgen Möller

Psychiatrische Klinik der Ludwig-Maximilians-Universität

Nußbaumstr. 7

80336 München

Phone: +89 5160 5501

Fax: +89 5160 5522

Email: hans-juergen.moeller@med.uni-muenchen.de